Why It Matters
Federal and state antitrust regulators have intensified scrutiny of healthcare markets, and Congress is taking notice. A House Judiciary Committee subcommittee hearing scheduled for September 14 will examine fraud and competition in healthcare, a sector where enforcement actions have accelerated sharply. The timing reflects mounting pressure on lawmakers to address pricing practices, algorithmic control of reimbursement rates, and consolidation that critics say reduces competition and inflates costs for patients and providers alike.
In June 2026, the Arizona Attorney General brought an action against MultiPlan and several other healthcare providers, alleging conspiracy to suppress reimbursement rates for out-of-network services using a pricing algorithm. That case exemplifies the kind of conduct now drawing scrutiny at the federal level.
The FTC's Healthcare Task Force has coordinated aggressive enforcement on mergers, pharmacy benefit manager (PBM) rebate practices, and restrictive payor activities throughout 2026. States have also tightened oversight, with California and Rhode Island instituting additional reporting requirements, including for private equity groups.
The 2026 National Health Care Fraud Takedown, a coordinated federal enforcement action, charged 455 defendants across 56 federal districts and 45 states and territories, with 90 of those charged being doctors and other licensed medical professionals. The alleged fraud exceeded $6.5 billion. That enforcement push underscores why Congress is convening to examine both the fraud landscape and the competitive dynamics that may enable it.
The Hearing
The Subcommittee on Administrative State, Regulatory Reform, and Antitrust of the House Judiciary Committee will hold the hearing "Examining Healthcare Markets: Fraud And Competition" on September 14. Sixteen House Judiciary Committee members are listed as committee members for this hearing.
Context
Regulatory activity in healthcare has been relentless. The FTC successfully challenged the Alcon/Lensar merger and the Edwards/JenaValve merger in the healthcare space. The FTC also required Sevita Health to divest more than 100 healthcare facilities to resolve antitrust concerns surrounding its proposed $835 million acquisition of BrightSpring Health Services, Inc.'s community living business.
UnitedHealth Group Inc., a major healthcare and insurance player, paid $120,000 for lobbying services in the second quarter of 2026, addressing general business issues, pharmacy benefit manager issues, Medicare Advantage, health insurance matters, and general healthcare competition issues. Better Solutions for Healthcare, an advocacy group, has consistently lobbied to promote hospital competition, enforce federal price transparency laws for hospital charges, rein in hospital price markups, and ensure honest billing practices by hospitals, spending $50,000 per quarter across recent filing periods.
The FTC revised statements covering physician networks and other health care multiprovider networks in August, emphasizing that the same antitrust principles governing all other industries apply to health care providers. The FTC's Healthcare Task Force maintains expertise in health care markets through research and reports on competition issues, including studies of generic drug entry, contact lens sales, and mail order pharmacy.
The Bottom Line
Healthcare market consolidation and pricing practices remain a focal point for both regulators and Congress. The hearing will likely surface tension between industry arguments about efficiency and competition advocates' concerns about market power. With federal and state enforcers already moving aggressively on multiple fronts (and private equity deals in healthcare now facing stricter state-level scrutiny), the subcommittee's examination could shape pressure on the FTC and state attorneys general to sustain or accelerate their current enforcement posture.
Spot something wrong? Report an issue with this article